EGFR (T790M/C797G/L858R)
Sign in to save this workspaceEGFR · Variant type: compound · HGVS: p.746_750del;p.T790M;p.L858R
Components
p.746_750delp.T790Mp.L858R
Drug response on this variant
| # | Drug | Inhibition on variant | Residual | KISS |
|---|---|---|---|---|
| 1 | Gilteritinib | 94.7% | 5.3% | 88.97 |
| 2 | Lazertinib | 91.0% | 9.0% | 97.47 |
| 3 | Pacritinib | 87.3% | 12.7% | 88.64 |
| 4 | Neratinib | 74.3% | 25.7% | 93.18 |
| 5 | Entrectinib | 71.6% | 28.4% | 93.69 |
| 6 | Mobocertinib | 66.3% | 33.7% | 97.22 |
| 7 | Canertinib | 60.5% | 39.5% | 96.49 |
| 8 | Erlotinib | 54.9% | 45.1% | 99.75 |
| 9 | Vandetanib | 53.0% | 47.0% | 95.74 |
| 10 | Repotrectinib | 46.5% | 53.5% | 84.21 |
| 11 | Fedratinib | 46.0% | 54.0% | 96.21 |
| 12 | Defactinib | 35.5% | 64.5% | 92.68 |
| 13 | Pralsetinib | 32.5% | 67.5% | 93.43 |
| 14 | Abemaciclib | 32.3% | 67.7% | 91.48 |
| 15 | Deucravacitinib | 29.3% | 70.7% | 98.99 |
| 16 | Pirtobrutinib | 25.0% | 75.0% | 99.49 |
| 17 | Sunitinib | 22.0% | 78.0% | 91.73 |
| 18 | Palbociclib | 16.5% | 83.5% | 98.75 |
| 19 | Darovasertib | 14.9% | 85.1% | 96.99 |
| 20 | Avapritinib | 13.7% | 86.3% | 97.73 |
| 21 | Quizartinib | 12.1% | 87.9% | 99.50 |
| 22 | Idelalisib | 11.6% | 88.4% | 100.00 |
| 23 | Alpelisib | 10.4% | 89.6% | 97.22 |
| 24 | Pexidartinib | 10.0% | 90.0% | 99.49 |
| 25 | Capmatinib | 8.4% | 91.6% | 99.75 |
Wild-type vs variant — drug response delta
Positive Δ means the drug hits the variant harder than wild-type (mutation-selective); negative Δ means it loses potency (resistance).
| Drug | Variant inh | WT inh | Δ (variant − WT) |
|---|---|---|---|
| Gilteritinib | 94.7% | 91.0% | +3.6% |
| Lazertinib | 91.0% | 100.0% | -9.0% |
| Pacritinib | 87.3% | — | — |
| Neratinib | 74.3% | 100.0% | -25.7% |
| Entrectinib | 71.6% | — | — |
| Mobocertinib | 66.3% | 100.0% | -33.7% |
| Canertinib | 60.5% | 98.4% | -38.0% |
| Erlotinib | 54.9% | 99.4% | -44.5% |
| Vandetanib | 53.0% | 99.3% | -46.3% |
| Repotrectinib | 46.5% | — | — |
| Fedratinib | 46.0% | — | — |
| Defactinib | 35.5% | 94.6% | -59.1% |
| Pralsetinib | 32.5% | 99.1% | -66.6% |
| Abemaciclib | 32.3% | — | — |
| Deucravacitinib | 29.3% | — | — |
| Pirtobrutinib | 25.0% | — | — |
| Sunitinib | 22.0% | — | — |
| Palbociclib | 16.5% | — | — |
| Darovasertib | 14.9% | — | — |
| Avapritinib | 13.7% | — | — |
| Quizartinib | 12.1% | — | — |
| Idelalisib | 11.6% | — | — |
| Alpelisib | 10.4% | — | — |
| Pexidartinib | 10.0% | — | — |
| Capmatinib | 8.4% | — | — |
Annotations
Sign in to read and post annotations.
Loading…
Served from saifudeen2026@1.0.0 · API 0.1.0 · 12.8ms